ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the third quarter of 2023.
- ARS Pharma expects to report its findings from this study in the first quarter of 2024.
- R&D Expenses: Research and development (R&D) expenses were $3.0 million for the quarter ended September 30, 2023.
- G&A Expenses: General and administrative (G&A) expenses were $15.0 million for the quarter ended September 30, 2023.
- Net Loss: Net loss was $14.9 million for the quarter ended September 30, 2023.